title: Fibroblast growth factors 2, 4, and 8 exert both negative and positive effects on limb, frontonasal, and mandibular chondrogenesis via MEK-ERK activation.
abstract: Fibroblast growth factors (FGFs) and their receptors play fundamental roles regulating growth, morphogenesis, and cartilage formation in embryonic limbs and facial primordia. However, the intracellular pathways that transduce FGF signals during the differentiation of pluripotent mesenchymal cells into chondrocytes are currently unknown. Our present study demonstrates that FGF8, 4, and 2 treatments exert both inhibitory and stimulatory effects on cartilage differentiation in micromass cultures prepared from mesenchymal cells of the chick embryo wing bud, frontonasal mass, and mandibular arch through activation of the MEK-ERK mitogen-activated protein kinase (MAPK) cascade. In cultures of stage 23/24 and stage 28/29 wing bud mesenchyme, as well as stage 24/25 and stage 28/29 frontonasal cells, FGF treatments depressed cartilage matrix production and decreased transcript levels for three cartilage-specific genes: col2a1, aggrecan, and sox9. Conversely, FGF treatment increased cartilage differentiation in cultures of stage 24/25 and stage 28/29 mandibular mesenchyme. In all cell types, FGF treatment elevated endogenous ERK phosphorylation. Moreover, both the stimulatory effects of FGFs on mandibular chondrogenesis, as well as the inhibitory effects of FGFs on wing mesenchyme and stage 24/25 frontonasal cells, were completely blocked when cultures were treated with MEK inhibitor U0126 or transfected with dominant negative ERK2. Thus, MEK-ERK activation is an essential component of the signal transduction pathway that mediates both positive and negative effects of FGFs 8, 4, and 2 on chondrogenesis in embryonic limb, mandibular, and early-stage frontonasal mesenchyme cells. Interestingly, the effects of FGF on late-stage frontonasal cells appear to be relayed by an ERK-independent system.
authors.affiliation: Department of Anatomy and Cell Biology, College of Medicine, University of Saskatchewan, Saskatoon, Canada.
authors.forename: Brent E
authors.initials: BE
authors.lastname: Bobick
authors.forename: Tasha M
authors.initials: TM
authors.lastname: Thornhill
authors.forename: William M
authors.initials: WM
authors.lastname: Kulyk
mesh_terms: D000818:Animals; D002070:Butadienes / Q000494:pharmacology; D002356:Cartilage / Q000378:metabolism; D002478:Cells, Cultured; D002642:Chick Embryo; D020219:Chondrogenesis / Q000187:drug effects*; D024043:Collagen Type II / Q000235:genetics; D004742:Enhancer Elements, Genetic / Q000187:drug effects; D004789:Enzyme Activation / Q000187:drug effects; D005109:Extracellular Matrix / Q000187:drug effects / Q000378:metabolism; D048049:Extracellular Signal-Regulated MAP Kinases / Q000378:metabolism*; D005145:Face / Q000196:embryology; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology; D051519:Fibroblast Growth Factor 4 / Q000494:pharmacology; D051524:Fibroblast Growth Factor 8 / Q000494:pharmacology; D005346:Fibroblast Growth Factors / Q000494:pharmacology*; D005799:Genes, Dominant; D006801:Humans; D008334:Mandible / Q000166:cytology / Q000187:drug effects / Q000196:embryology / Q000201:enzymology*; D008648:Mesoderm / Q000166:cytology / Q000187:drug effects; D020929:Mitogen-Activated Protein Kinase Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism*; D009570:Nitriles / Q000494:pharmacology; D010766:Phosphorylation / Q000187:drug effects; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D014921:Wings, Animal / Q000166:cytology / Q000187:drug effects / Q000196:embryology / Q000201:enzymology*
chemical_list: D002070:Butadienes; D024043:Collagen Type II; D051519:Fibroblast Growth Factor 4; D009570:Nitriles; D012333:RNA, Messenger; C113580:U 0126; D016222:Fibroblast Growth Factor 2; D051524:Fibroblast Growth Factor 8; D005346:Fibroblast Growth Factors; D048049:Extracellular Signal-Regulated MAP Kinases; D020929:Mitogen-Activated Protein Kinase Kinases